Iran J Pediatr. 2015 Aug;25(4):e453. doi: 10.5812/ijp.453. Epub 2015 Aug 24.

Safety and Efficacy of Intravenous Colistin in Neonates With Culture Proven Sepsis.

Iranian journal of pediatrics

Kadir Serafettin Tekgunduz, Mustafa Kara, Ibrahim Caner, Yasar Demirelli

PMID: 26396706 PMCID: PMC4575804 DOI: 10.5812/ijp.453

Abstract

BACKGROUND: Although it is well described among adults, intravenous colistin use and its associated toxicities in newborns are poorly understood.

OBJECTIVES: We present our experience of efficacy and safety of intravenous colistin in the treatment of sepsis in term and preterm neonates.

PATIENTS AND METHODS: The records of neonates who received colistin between January 2013 and February 2014 were retrospectively reviewed. All neonates with culture proven nosocomial infections due to multidrug resistant organisms and treated continuously with colistin for more than 72 hours were included in the study.

RESULTS: Patients were evaluated for clinical and microbiological response to the drug and its and side effects. Twelve newborn infants with mean 31.8 ± 3.5 weeks gestational age and median 1482 (810 - 3200) gram birth weight were included. 11/12 (91.7%) patients showed microbiological clearance with intravenous colistin. One patient who had recurrent cerebrospinal fluid positive culture was treated with intraventricular colistin. The major side effects observed was hyponatremia and hypokalemia in 2 (16.6%) patients, all infants required magnesium supplementation.

CONCLUSIONS: Intravenous colistin administration appears to be safe and efficacious for multidrug-resistant gram-negative infections in neonates, including preterm infants. However, we believe that large prospective controlled studies are needed to confirm its efficacy and safety in neonates.

Keywords: Colistin; Infection; Multidrug Resistance; Neonate; Preterm Infant; Sepsis

References

1. Pediatr Infect Dis J. 2011 Mar;30(3):218-21 - PubMed
2. Pediatr Int. 2010 Jun;52(3):410-4 - PubMed
3. Int J Antimicrob Agents. 2009 Jun;33(6):503.e1-503.e13 - PubMed
4. Int J Antimicrob Agents. 2013 Jun;41(6):499-508 - PubMed
5. Antimicrob Agents Chemother. 2003 Mar;47(3):905-9 - PubMed
6. Int J Antimicrob Agents. 2010 Mar;35(3):297-300 - PubMed
7. Int J Antimicrob Agents. 2007 Jan;29(1):9-25 - PubMed
8. Antimicrob Agents Chemother. 2010 Sep;54(9):3985-7 - PubMed
9. Indian J Crit Care Med. 2009 Apr-Jun;13(2):49-53 - PubMed
10. J Burn Care Res. 2009 Jul-Aug;30(4):612-5 - PubMed
11. Ren Fail. 2013;35(3):411-3 - PubMed
12. Am J Infect Control. 2008 Jun;36(5):309-32 - PubMed
13. Eur J Pediatr. 2010 Jul;169(7):867-74 - PubMed
14. Pediatr Crit Care Med. 2013 Jul;14(6):e268-72 - PubMed
15. Antimicrob Agents Chemother. 2009 Nov;53(11):4907-10 - PubMed
16. Clin Infect Dis. 2004 Nov 1;39(9):1267-84 - PubMed
17. Ann Intern Med. 1970 Jun;72(6):857-68 - PubMed
18. Am J Perinatol. 2014 Dec;31(12):1079-86 - PubMed
19. Int J Antimicrob Agents. 2012 Aug;40(2):140-4 - PubMed
20. Mikrobiyol Bul. 2011 Oct;45(4):716-22 - PubMed
21. Int J Infect Dis. 2010 Jul;14(7):e572-9 - PubMed
22. Clin Microbiol Infect. 2005 Feb;11(2):115-21 - PubMed
23. Clin Infect Dis. 2003 May 1;36(9):1111-8 - PubMed
24. Ann Intensive Care. 2011 May 25;1(1):14 - PubMed
25. Euro Surveill. 2008 Nov 20;13(47):null - PubMed
26. Intern Med. 2011;50(9):1009-13 - PubMed
27. Ann Fr Anesth Reanim. 2011 Nov;30(11):854-5 - PubMed
28. Pediatr Infect Dis J. 2013 Jan;32(1):17-22 - PubMed
29. Indian J Crit Care Med. 2008 Oct;12(4):153-7 - PubMed
30. Clin Microbiol Infect. 2008 Sep;14(9):816-27 - PubMed
31. Curr Opin Infect Dis. 2009 Dec;22(6):535-43 - PubMed

Publication Types

• Journal Article